drugset / Trial / NCT05483894

Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial

NCT05483894

Phase 2 Unknown 36 enrolled Samsung Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension

Timeline

Start
2022-08-01
Primary completion
2024-07-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg